Background Renal cell carcinoma (RCC) represents the 15th most common cancer worldwide. About 20% of patients with renal cell carcinoma eventually develop liver metastasis (LM). Furthermore, the liver is the only site of distant spread […]
Kazakhstan is a country in Central Asia with a high rate of gastric cancer. The development of gastric cancer is predisposed by a combination of genetic and environmental factors including dietary habits. With the advance […]
Despite the numerous developments in the diagnosis and treatment of gastric cancer, it continues to be an important public health problem. Therefore, besides classical methods, the new biomolecules are needed to facilitate the prediction of […]
Le et al. recently reported (Science 10.1126/science.aan6733 (2017); (ClinicalTrials.gov number, NCT01876511) on the success of immune checkpoint blockade with anti-PD-1 antibodies in the patients whose cancers exhibited microsatellite instability-high (MSI-H) status. The study included 12 […]
Targeted therapy based on the immune checkpoint inhibitors (Anti-PD1/PD-L1) has revolutionized cancer treatment and outcome of several solid and hematologic malignancies, including non-small cell lung carcinoma (NSCLC), metastatic renal cell carcinoma, metastatic malignant melanoma, advanced/metastatic […]
It is becoming clear that tumor consists of heterogeneous cells. These cells are different one to another in terms of their capacity to proliferate and to survive against cancer therapy, such as chemotherapy, radiotherapy and […]
Copyright (c) 2019 Association of Basic Medical Sciences of FBIH